Polio Outbreak in Pakistan
Pakistan continues to be dealing with a polio outbreak as four fresh cases have emerged, pushing the national tally to 37 this year, according to health officials on October 19, 2024. Health officials said that the regional reference laboratory for polio eradication at the National Institute of Health in Islamabad confirmed wild poliovirus type-1 (WPV1) in two children-one from each Balochistan and Khyber-Pakhtunkhwa.
In recent cases, a girl has been affected from Pishin, and two boys from Chaman and Noshki of Balochistan, and a girl from Lakki Marwat in KP. These are the first detections of the virus within Noshki and Lakki Marwat this year; isolated cases of poliovirus were previously reported within Chaman and Pishin. The province of Balochistan was the worst hit with 20 cases, Sindh had 10, Khyber Pakhtunkhwa had five, and Punjab and Islamabad had one case each.
A gigantic fight against polio has been on going in Pakistan- especially in Balochistan and southern KP-over the last two years. Immunisation campaigns have often been suspended or delayed because of local protests, insecurity, and community boycotts. Consequently, quite a number of children did not get the necessary vaccinations, making existing patches of vulnerability for the virus to flow within those pockets.
Noshki, located near Afghanistan's border, and Lakki Marwat have also recently reported some positive environmental samples that confirm the virus is present here, said a local reference laboratory official. Samples of latest cases are currently under genetic sequencing for checking spread of virus and origin.
As the threat of polio continues to grow, Pakistan has vowed to mount a nationwide campaign against it beginning from October 28. With the zeal to tackle the menace in the most effective manner, over 45 million children under the age of five will be vaccinated across the country.
Today, Afghanistan and Pakistan remain one of the few countries where polio has not yet been eradicated. The WHO said the virus remains a potential serious public health threat in areas with low vaccination coverage and weak surveillance.
The country declared itself polio-free since 2014 and has kept the disease on bay almost a decade with very robust vaccination programs; however, two cases of vaccine-derived poliovirus cases reported in recent days from Meghalaya create some amount of doubts over a possible resurgence. Experts observe that in India, despite these detections taking place, strong coverage of vaccination at 90-95% and mandatory surveillance measures keep the risk of this widespread outbreak at bay.
The experts point out, however, that such stable situation in India requires continued surveillance. "Countries like Pakistan and parts of Africa remain at a high risk because vaccination rates in those areas are much lower," Dr. Siddharth, public health expert, said. Vaccination is an indispensable act in order to avoid the spread of this incapacitating disease that manifests most importantly as a nervous system affliction leading to the paralysis of a long period.
With concerted efforts from health authorities, there is hope someday that the scourge of polio will be completely eradicated from the face of the earth and future generations will never suffer from its effects.
Credit: iStock
In a major scientific breakthrough, researchers at Stanford University have used artificial intelligence (AI) to design entirely new viruses that do not exist in nature.
The AI-generated viruses successfully killed Escherichia coli (E. coli) bacteria that had become resistant to naturally occurring bacteriophages (phages)—viruses that infect and destroy bacteria—offering new hope for tackling antibiotic-resistant infections.
The study, published in the journal Science, also raises important biosafety concerns, as the same technology could potentially be misused to design harmful pathogens.
Chemical engineer Brian Hie and bioengineering graduate student Samuel King developed Evo 2, a generative AI model capable of writing complete DNA sequences and designing entirely new genomes.
The researchers focused on bacteriophages, viruses that infect bacteria and are already being explored as alternatives to antibiotics for treating difficult bacterial infections.
Using genomes designed by Evo 2, the team synthesized nearly 300 novel phages and tested them against E. coli. From these, they identified 16 highly effective phages that successfully killed bacteria resistant to naturally occurring phages.
The researchers believe the ability to rapidly design customized phages could transform phage therapy and expand the arsenal against antibiotic-resistant bacteria.
The team redesigned bacteriophage ΦX174, one of the simplest known viruses. Despite its small size, ΦX174 efficiently infects and kills bacteria, making it a valuable model for developing new phage therapies.
One of the biggest challenges in infectious disease treatment is that bacteria eventually develop resistance to antibiotics—and even to individual phages. To overcome this, the researchers designed a genetically diverse cocktail of 16 AI-created phages.
"If the bacteria gain resistance to a single phage, it's game over for the medication," Hie said. "But if you have multiple genetically distinct phages in a mixture, it would be harder for the bacteria to develop resistance to the entire cocktail."
The team showed that the phage cocktail successfully eliminated E. coli strains that had become resistant to the natural ΦX174 virus.
"We have a proof of concept in the paper, where we show that this cocktail of 16 phages rapidly overcomes resistance in E. coli that is immune to native ΦX174," Hie said.
Researchers believe the same AI-driven approach could eventually be used to develop phages against other drug-resistant bacteria, including:
If successful, AI-designed phage cocktails could provide a powerful alternative to conventional antibiotics, whose effectiveness continues to decline because of antimicrobial resistance.
The researchers have made Evo 2 freely available as open-source software, allowing scientists around the world to design and study new genomes.
While this could accelerate advances in medicine and biotechnology, experts say it also highlights the urgent need for stronger oversight.
"The ability to compose viral genomes using generative AI now exists; the governance to safely steer it does not," wrote Prof. Tom Inglesby and Dr. Moritz Hanke of the Center for Health Security at Johns Hopkins University in an accompanying Science commentary.
Tom Ellis, Professor of Synthetic Genome Engineering at Imperial College London, described the research as impressive but cautioned that AI could theoretically be used to design harmful viruses if trained on the genetic code of dangerous pathogens, The Guardian reported.
However, he said safeguards—such as restricting access to sensitive genetic data and screening synthetic genomes before they are manufactured—could help reduce those risks.
Credit: AP Photo
The Donald Trump administration is reportedly considering an executive order focused on the US childhood vaccination schedule and autism research, despite decades of scientific evidence showing no link between vaccines and autism.
According to a Washington Post report citing official sources, the proposed order would examine the childhood immunization schedule and autism research. However, its scope and timing have not been finalized and could still change.
The move comes even as some of Trump's political advisers have reportedly warned that elevating the issue could hurt Republican candidates ahead of the November midterm elections.
According to The Wall Street Journal, Trump wants "alleviating autism" to become part of his presidential legacy and has privately expressed frustration that US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has not gone far enough in reducing the recommended childhood vaccination schedule. The report also said Trump believes that reducing the number of recommended childhood vaccines could lower autism rates.
In recent months, Trump has urged senior administration officials, including Kennedy Jr., to increase scrutiny of childhood vaccines.
Last year, Kennedy had cancelled roughly $500 million in mRNA vaccine research grants and replaced every member of a federal immunization advisory panel. However, he has been relatively quiet on vaccine policy this year after White House aides reportedly advised that vaccine skepticism was unpopular with many voters.
Medical experts continue to emphasize that extensive research has found no evidence that vaccines cause autism.
"Donald Trump has been anti-vaccine at least since 2015," Dr. Paul Offit, Director of the Vaccine Education Center and an infectious disease specialist at Children's Hospital of Philadelphia, was quoted as saying by CNN.
During the 2015 Republican primary debate, Trump claimed autism had gotten "totally out of control" and suggested vaccines should be administered in "smaller doses over a longer period of time."
Trump has repeatedly suggested there may be a connection between vaccines and autism, despite overwhelming scientific evidence disproving the claim. He has also argued that the US childhood vaccination schedule should be reduced, raising concerns among public health experts.
"I believe in vaccines, but I don't believe that, you know, you have to have a mandate for all of them," Trump said in a May interview with journalist Sharyl Attkisson. "I really feel that vaccines, if they were given in smaller quantities—they want to cut some out, and that's good, too. I agree with that."
Multiple large-scale studies conducted over the past two decades have consistently found no causal link between childhood vaccines—including the MMR vaccine—and autism spectrum disorder.
Major health organizations, including the World Health Organization (WHO) and the US Centers for Disease Control and Prevention (CDC), continue to recommend routine childhood immunization as one of the safest and most effective ways to prevent infectious diseases.
Credit: Grimsby Town FC
Alex Hughes, the son of former Wales and Manchester United footballer Mark Hughes, has died at the age of 38 from Sudden Arrhythmic Death Syndrome (SADS), also known as Sudden Adult Death Syndrome.
Alex Hughes, who served as Grimsby Town's Head of Player Recruitment, was found collapsed on the bedroom floor of his Cheshire home by his two sons at around 7 a.m. on June 19, an inquest at Cheshire Coroner's Court heard.
According to the hearing, Alex's eldest son immediately began CPR before paramedics arrived. Despite prolonged resuscitation efforts, emergency responders were unable to revive him.
Area Coroner Victoria Davies concluded that Hughes died from Sudden Arrhythmic Death Syndrome (SADS), a condition in which a fatal heart rhythm abnormality causes sudden cardiac arrest even though the heart appears structurally normal during a post-mortem examination.
Following his death, Mark Hughes and his wife, Jill, said they were "totally heartbroken by the sudden and unexpected loss of our beloved son."
SADS refers to a sudden, unexpected death caused by an abnormal heart rhythm in people whose hearts appear structurally normal after death. The condition is most commonly linked to inherited disorders that affect the heart's electrical system, triggering life-threatening irregular heart rhythms (arrhythmias) that can lead to sudden cardiac arrest.
According to the British Heart Foundation, around 500 people die from SADS each year in the UK, with young adults—particularly men—being most commonly affected.
Most cases of SADS are caused by inherited genetic conditions that interfere with the heart's electrical signals. Because these disorders often cause few or no symptoms, many people remain unaware they have them until a cardiac arrest occurs.
Early diagnosis through cardiac evaluation and family screening can help identify those at risk and prevent sudden deaths.
Several inherited heart rhythm disorders are associated with SADS, including:
Many people with inherited heart rhythm disorders experience no warning signs. However, symptoms that warrant medical evaluation include:
© 2024 Bennett, Coleman & Company Limited